Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

In vitro activity of ceftazidime/avibactam, imipenem/relebactam and meropenem/vaborbactam alone or in combination with polymyxin B against carbapenem resistant Acinetobacter baumannii

The Journal of Antibiotics (2023)Cite this article

Subjects

Abstract

Nosocomial infection caused by Carbapenem-Resistant Acinetobacter baumannii (CR-A. baumannii) has become a challenge in clinical practice. Acting as the last resort antibacterial agents for the treatment of CR-A. baumannii infection, polymyxins have high risk of nephrotoxicity and poor clinical efficacy. Ceftazidime/avibactam, imipenem/relebactam and meropenem/vaborbactam are three β-lactam/β-lactamase inhibitor combination complexes that newly approved by the Food and Drug Administration for the treatment of carbapenem-resistant Gram-negative bacterial infection. In this study, we analyzed the in vitro activity of those novel antibacterial agents alone or in combination with polymyxin B against the CR-A. baumannii obtained from a Chinese tertiary hospital. Our results suggest that those novel antibacterial agents should not be used alone for the treatment of CR-A. baumannii infection, as they cannot prevent the regrowth of bacteria at the clinical achievable blood concentration. Imipenem/relebactam and meropenem/vaborbactam should not be used as the substitutes of imipenem and meropenem for polymyxin B based combination therapy against CR-A. baumannii, since they have no edge over imipenem and meropenem on antibacterial activity when in combination with polymyxin B. Ceftazidime/avibactam may be more suitable than ceftazidime for polymyxin B based combination therapy against CR-A. baumannii, as it has a higher synergistic rate with polymyxin B, and the antibacterial activity of ceftazidime/avibactam is much higher than that of ceftazidime when tested in combination with polymyxin B. Ceftazidime/avibactam may also be the better choice than imipenem and meropenem for polymyxin B based combination therapy against CR-A. baumannii, as it has a higher synergistic rate with polymyxin B.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Get just this article for as long as you need it

$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

References

  1. Viehman JA, Nguyen MH, Doi Y. Treatment options for carbapenem-resistant and extensively drug-resistant Acinetobacter baumannii infections. Drugs. 2014;74:1315–33.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Vázquez-López R, Solano-Gálvez SG, Juárez Vignon-Whaley JJ, Abello Vaamonde JA, Padró Alonzo LA, Rivera Reséndiz A, et al. Acinetobacter baumannii resistance: a real challenge for clinicians. Antibiotics (Basel). 2020;9:205.

    Article  PubMed  Google Scholar 

  3. Ibrahim S, Al-Saryi N, Al-Kadmy IMS, Aziz SN. Multidrug-resistant Acinetobacter baumannii as an emerging concern in hospitals. Mol Biol Rep. 2021;48:6987–98.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States, 2019[M]. US Department of Health and Human Services, Centres for Disease Control and Prevention, 2019.

  5. Hu F, Guo Y, Yang Y, Zheng Y, Wu S, Jiang X, et al. China Antimicrobial Surveillance Network (CHINET) Study Group. Resistance reported from China antimicrobial surveillance network (CHINET) in 2018. Eur J Clin Microbiol Infect Dis. 2019;38:2275–81.

    Article  CAS  PubMed  Google Scholar 

  6. Tacconelli E, Carrara E, Savoldi A, Harbarth S, Mendelson M, Monnet DL, et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis. 2018;18:318–27.

    Article  PubMed  Google Scholar 

  7. Satlin MJ, Lewis JS, Weinstein MP, Patel J, Humphries RM, Kahlmeter G, et al. Clinical and Laboratory Standards Institute and European Committee on Antimicrobial Susceptibility Testing Position Statements on Polymyxin B and Colistin Clinical Breakpoints. Clin Infect Dis. 2020;71:e523–e529.

    CAS  PubMed  Google Scholar 

  8. Wang Y, Ma X, Zhao L, He Y, Yu W, Fu S, et al. Heteroresistance is associated with in vitro regrowth during colistin treatment in carbapenem-resistant Klebsiella pneumoniae. Front Microbiol. 2022;13:868991.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Tsuji BT, Pogue JM, Zavascki AP, Paul M, Daikos GL, Forrest A, et al. International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP). Pharmacotherapy. 2019;39:10–39.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Sobieszczyk ME, Furuya EY, Hay CM, Pancholi P, Della-Latta P, Hammer SM, et al. Combination therapy with polymyxin B for the treatment of multidrug-resistant Gram-negative respiratory tract infections. J Antimicrob Chemother. 2004;54:566–9.

    Article  CAS  PubMed  Google Scholar 

  11. Ni W, Shao X, Di X, Cui J, Wang R, Liu Y. In vitro synergy of polymyxins with other antibiotics for Acinetobacter baumannii: a systematic review and meta-analysis. Int J Antimicrob Agents. 2015;45:8–18.

    Article  CAS  PubMed  Google Scholar 

  12. Lenhard JR, Nation RL, Tsuji BT. Synergistic combinations of polymyxins. Int J Antimicrob Agents. 2016;48:607–13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Yusuf E, Bax HI, Verkaik NJ, van Westreenen M. An update on eight “new” antibiotics against multidrug-resistant gram-negative bacteria. J Clin Med. 2021;10:1068.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Zhanel GG, Lawrence CK, Adam H, Schweizer F, Zelenitsky S, Zhanel M, et al. Imipenem-relebactam and meropenem-vaborbactam: two novel carbapenem-β-lactamase inhibitor combinations. Drugs. 2018;78:65–98.

    Article  CAS  PubMed  Google Scholar 

  15. El Hafi B, Rasheed SS, Abou Fayad AG, Araj GF, Matar GM. Evaluating the efficacies of carbapenem/β-lactamase inhibitors against carbapenem-resistant gram-negative bacteria in vitro and in vivo. Front Microbiol. 2019;10:933.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Kuo SC, Wang YC, Tan MC, Huang WC, Shiau YR, Wang HY, et al. In vitro activity of imipenem/relebactam, meropenem/vaborbactam, ceftazidime/avibactam, cefepime/zidebactam and other novel antibiotics against imipenem-non-susceptible Gram-negative bacilli from Taiwan. J Antimicrob Chemother. 2021;76:2071–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Zhang H, Jia P, Zhu Y, Zhang G, Zhang J, Kang W, et al. Susceptibility to imipenem/relebactam of Pseudomonas aeruginosa and Acinetobacter baumannii isolates from Chinese intra-abdominal, respiratory and urinary tract infections: SMART 2015 to 2018. Infect Drug Resist. 2021;14:3509–18.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Shields RK, Potoski BA, Haidar G, Hao B, Doi Y, Chen L, et al. Clinical outcomes, drug toxicity, and emergence of ceftazidime-avibactam resistance among patients treated for carbapenem-resistant Enterobacteriaceae infections. Clin Infect Dis. 2016;63:1615–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Shah PJ, Tran T, Emelogu F, Tariq F. Aztreonam, Ceftazidime/Avibactam, and colistin combination for the management of carbapenemase-producing Klebsiella pneumoniae bacteremia: a case report. J Pharm Pract. 2021;34:653–7.

    Article  PubMed  Google Scholar 

  20. Khorsi K, Messai Y, Hamidi M, Ammari H, Bakour R. High prevalence of multidrug-resistance in Acinetobacter baumannii and dissemination of carbapenemase-encoding genes blaOXA-23-like, blaOXA-24-like and blaNDM-1 in Algiers hospitals. Asian Pac J Trop Med. 2015;8:438–46.

    Article  CAS  PubMed  Google Scholar 

  21. Bertini A, Poirel L, Bernabeu S, Fortini D, Villa L, Nordmann P, et al. Multicopy blaOXA-58 gene as a source of high-level resistance to carbapenems in Acinetobacter baumannii. Antimicrob Agents Chemother. 2007;51:2324–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Ambler RP, Coulson AF, Frère JM, Ghuysen JM, Joris B, Forsman M, et al. A standard numbering scheme for the class A beta-lactamases. Biochem J. 1991;276:269–70.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Queenan AM, Bush K. Carbapenemases: the versatile beta-lactamases. Clin Microbiol Rev. 2007;20:440–58.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Nordmann P, Dortet L, Poirel L. Carbapenem resistance in Enterobacteriaceae: here is the storm! Trends Mol Med. 2012;18:263–72.

    Article  CAS  PubMed  Google Scholar 

  25. Kuiper SG, Leegwater E, Wilms EB, van Nieuwkoop C. Evaluating imipenem + cilastatin + relebactam for the treatment of complicated urinary tract infections. Expert Opin Pharmacother. 2020;21:1805–11.

    Article  CAS  PubMed  Google Scholar 

  26. Groft LM, Claeys KC, Heil EL. An evaluation of meropenem/vaborbactam for the treatment of nosocomial pneumonia. Expert Opin Pharmacother. 2021;22:265–71.

    Article  CAS  PubMed  Google Scholar 

  27. Savov E, Trifonova A, Kovachka K, Kjosseva E, Strateva T. Antimicrobial in vitro activities of ceftazidime-avibactam, meropenem-vaborbactam and plazomicin against multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa - a pilot Bulgarian study. Infect Dis (Lond). 2019;51:870–3.

    Article  PubMed  Google Scholar 

  28. Lomovskaya O, Sun D, Rubio-Aparicio D, Nelson K, Tsivkovski R, Griffith DC, et al. Vaborbactam: spectrum of beta-lactamase inhibition and impact of resistance mechanisms on activity in Enterobacteriaceae. Antimicrob Agents Chemother. 2017;61:e01443–17.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Hamidian M, Nigro SJ. Emergence, molecular mechanisms and global spread of carbapenem-resistant Acinetobacter baumannii. Micro Genom. 2019;5:e000306.

    Google Scholar 

  30. Yu H, Ezpeleta-Lobato G, Han X, Carmona-Cartaya Y, Quiñones-Pérez D. Carbapenamase-producing Acinetobacter baumannii in China, Latin America and the Caribbean. MEDICC Rev. 2022;24:59–69.

    Article  PubMed  Google Scholar 

  31. Poirel L, Naas T, Nordmann P. Diversity, epidemiology, and genetics of class D beta-lactamases. Antimicrob Agents Chemother. 2010;54:24–38.

    Article  CAS  PubMed  Google Scholar 

  32. Poirel L, Nordmann P. Carbapenem resistance in Acinetobacter baumannii: mechanisms and epidemiology. Clin Microbiol Infect. 2006;12:826–36.

    Article  CAS  PubMed  Google Scholar 

  33. Fomnya HJ, Ngulde SI, Amshi KA, Bilbonga G. Antibiotics: classifications and mechanism of resistance[J]. Appl Microbiol Biotechnol. 2021;9:38–50.

    Google Scholar 

  34. Lee CR, Lee JH, Park M, Park KS, Bae IK, Kim YB, et al. Biology of Acinetobacter baumannii: Pathogenesis, antibiotic resistance mechanisms, and prospective treatment options. Front Cell Infect Microbiol. 2017;7:55.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Bowers DR, Cao H, Zhou J, Ledesma KR, Sun D, Lomovskaya O, et al. Assessment of minocycline and polymyxin B combination against Acinetobacter baumannii. Antimicrob Agents Chemother. 2015;59:2720–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Olsson A, Wistrand-Yuen P, Nielsen EI, Friberg LE, Sandegren L, Lagerbäck P, et al. Efficacy of antibiotic combinations against multidrug-resistant Pseudomonas aeruginosa in automated time-lapse microscopy and static time-kill experiments. Antimicrob Agents Chemother. 2020;64:e02111–19.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Wickremasinghe H, Yu HH, Azad MAK, Zhao J, Bergen PJ, Velkov T, et al. Clinically relevant concentrations of polymyxin B and meropenem synergistically kill multidrug-resistant Pseudomonas aeruginosa and minimize biofilm formation. Antibiotics (Basel). 2021;10:405.

    Article  CAS  PubMed  Google Scholar 

  38. Montero MM, Domene Ochoa S, López-Causapé C, VanScoy B, Luque S, Sorlí L, et al. Colistin plus meropenem combination is synergistic in vitro against extensively drug-resistant Pseudomonas aeruginosa, including high-risk clones. J Glob Antimicrob Resist. 2019;18:37–44.

    Article  PubMed  Google Scholar 

  39. Xie J, Roberts JA, Lipman J, Cai Y, Wang H, Zhao N, et al. Pharmacokinetic/pharmacodynamic adequacy of polymyxin B against extensively drug-resistant Gram-negative bacteria in critically ill, general ward and cystic fibrosis patient populations. Int J Antimicrob Agents. 2020;55:105943.

    Article  CAS  PubMed  Google Scholar 

  40. Manchandani P, Zhou J, Babic JT, Ledesma KR, Truong LD, Tam VH. Role of renal drug exposure in polymyxin B-induced nephrotoxicity. Antimicrob Agents Chemother. 2017;61:e02391–16.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

The authors are grateful to the Shiyan Renmin Hospital of Hubei University of Medicine and the Ningbo Yinzhou No.2 Hospital of Ningbo University. This work was supported by Shiyan Science and Technology Bureau (Grant No: 20Y46).

Author information

Author notes

  1. These authors contributed equally: Rongxin Liang, Dongxing Wang

Authors and Affiliations

  1. Department of Clinical Laboratory, Renmin Hospital, Hubei University of Medicine, Shiyan, Hubei, 442000, P. R. China

    Rongxin Liang, Dongxing Wang, Yuxia Gu, Meijun Wang, Dan Hu & Mingan Zhu

  2. Department of Gynecology, Renmin Hospital, Hubei University of Medicine, Shiyan, Hubei, 442000, P. R. China

    Mingjin Hu

  3. Department of ophthalmology, Ningbo Yinzhou No.2 Hospital, Medical School of Ningbo University, Ningbo, Zhejiang, 315000, P. R. China

    Meng Wang

Authors
  1. Rongxin Liang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dongxing Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mingjin Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yuxia Gu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Meijun Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Dan Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Mingan Zhu
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Meng Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

MW designed this research. RX and DX took charge of this study and finished the majority of experiments. RX drafted the manuscript and MA revised the manuscript critically for important intellectual content. MJ, YX, MJ, and DH participated in the collection of CR-A. baumannii isolates and gene information analysis.

Corresponding authors

Correspondence to Mingan Zhu or Meng Wang.

Ethics declarations

Conflict of interest

The authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Liang, R., Wang, D., Hu, M. et al. In vitro activity of ceftazidime/avibactam, imipenem/relebactam and meropenem/vaborbactam alone or in combination with polymyxin B against carbapenem resistant Acinetobacter baumannii. J Antibiot (2023). https://doi.org/10.1038/s41429-023-00631-0

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1038/s41429-023-00631-0

Search

Advanced search

Quick links